Add to ORKGlarge randomized, clinical trial, rivaroxaban was noninferior to war-farin in preventing stroke or systemic embolism in patients with atrial fibrillation. Objective: To determine the efficacy and safety of rivaroxaban compared with warfarin among vitamin K antagonist (VKA)–naive and VKA-experienced patients. Design: Prespecified subgroup analysis. (ClinicalTrials.gov: NCT00403767
BACKGROUND: All evidence regarding benefits and harms of rivaroxaban for stroke prevention has not b...
ACS: Acute Coronary Syndrome; AF: Atrial Fibrillation; DAPT: Dual Antiplatelet Therapy; INR: Interna...
BACKGROUND: Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary i...
C1 - Journal Articles RefereedBACKGROUND: In ROCKET AF, rivaroxaban was non-inferior to adjusted-dos...
AF) trial, the efficacy and safety of rivaroxaban, a novel, oral, direct factor Xa inhibitor, was as...
Background: Imitating the design of a randomized controlled trial in an observational study is one o...
International audienceBACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patient...
Aims We investigated clinical characteristics and outcomes of patients with significant valvular dis...
Rivaroxaban reduced stroke and systemic embolism compared with warfarin in nonvalvular AF Patel MR, ...
International audienceBackground and Purpose- We compared the 1-year safety and effectiveness of riv...
Alexander GG Turpie Department of Medicine, McMaster University, Hamilton, ONT, Canada Abstract: At...
Introduction: Several comparative real-world effectiveness studies on direct oral anticoagulants (DO...
International audienceBACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fi...
BACKGROUND: All evidence regarding benefits and harms of rivaroxaban for stroke prevention has not b...
ACS: Acute Coronary Syndrome; AF: Atrial Fibrillation; DAPT: Dual Antiplatelet Therapy; INR: Interna...
BACKGROUND: Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary i...
C1 - Journal Articles RefereedBACKGROUND: In ROCKET AF, rivaroxaban was non-inferior to adjusted-dos...
AF) trial, the efficacy and safety of rivaroxaban, a novel, oral, direct factor Xa inhibitor, was as...
Background: Imitating the design of a randomized controlled trial in an observational study is one o...
International audienceBACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patient...
Aims We investigated clinical characteristics and outcomes of patients with significant valvular dis...
Rivaroxaban reduced stroke and systemic embolism compared with warfarin in nonvalvular AF Patel MR, ...
International audienceBackground and Purpose- We compared the 1-year safety and effectiveness of riv...
Alexander GG Turpie Department of Medicine, McMaster University, Hamilton, ONT, Canada Abstract: At...
Introduction: Several comparative real-world effectiveness studies on direct oral anticoagulants (DO...
International audienceBACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fi...
BACKGROUND: All evidence regarding benefits and harms of rivaroxaban for stroke prevention has not b...
ACS: Acute Coronary Syndrome; AF: Atrial Fibrillation; DAPT: Dual Antiplatelet Therapy; INR: Interna...
BACKGROUND: Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary i...